



## Advances and Applications of Regulatory Genomics in Multiple Myeloma

Guest Editor:

### Dr. Valentina S. Caputo

1. Cancer Biology and Therapy,  
School of Applied Sciences,  
London South Bank University,  
London, UK

2. Hugh & Josseline Langmuir  
Centre for Myeloma Research,  
Centre for Haematology,  
Department of Immunology and  
Inflammation, Imperial College  
London, London, UK

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editor

This Special Issue will mainly focus on the study and application of the several layers of genetic regulation that are fundamental for multiple myeloma development, progression, extramedullary disease, resistance and relapse.

Potential topics include but are not limited to:

- Defining and characterising the myeloma and myeloma bone marrow's microenvironment epigenome and its changes during disease progression
- The correlation between genetic and epigenetic alterations to define myeloma subgroups
- The role of non-coding genome in myeloma development and progression
- The role of microRNA in myeloma development and progression
- The role of epigenetic regulation in myeloma plasticity
- Epi-drugs and their application in myeloma therapy
- Recent advances in epigenetic biomarkers for their use in diagnostics, patients' stratification and prognosis
- Use of epigenetic/gene-regulatory drugs for target resistance and relapse (pharmacological, immune or cellular therapy)
- Single-cell multi-omics approaches to define gene-regulatory networks





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)